Results 41 to 50 of about 317,404 (266)
siRNA applications in nanomedicine [PDF]
WIREs Nanomedicine and Nanobiotechnology, 2010 AbstractThe ability to specifically silence genes using RNA interference (RNAi) has wide therapeutic applications for the treatment of disease or the augmentation of tissue formation. RNAi is the sequence‐specific gene silencing mediated by a 21–25 nucleotide double‐stranded small interfering RNA (siRNA) molecule.
Talar, Tokatlian, Tatiana, Segura
openaire +2 more sources
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Российский кардиологический журналPatients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given
M. A. Simonenko +3 more
doaj +1 more source
Genotyping and siRNA-Mediated Quorum Sensing Inhibition in Staphylococcus aureus: Exploring New Approaches for Treating Persistent Infections [PDF]
Journal of Bioscience and Applied ResearchEmersion of persistent Staphylococcus aureus requires original research and developmental planning. Repression of virulence genes might be a committed therapeutic approach in this regard. Gene-quenching with short interfering RNA (siRNA) is considered an
Tabark Qader, Munim Ali, Ali Alsakini
doaj +1 more source
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Molecular Oncology, EarlyView.BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source
Revision of some species of Cenomanian caprinid rudists instituted by G. G. Gemmellaro in 1865
Revista Mexicana de Ciencias Geológicas, 2019 Gemmellaro erected in 1865 the species Caprinella caput-equi, C. gigantean, C. sharpie and C. bicarinata… in order to continue, download the full paper in PDF.
Salvio Bonanno, Giuseppe Sirna
doaj
Molecular Oncology, EarlyView.LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
OncoImmunology, 2018 TGFβ secreted by tumor cells and/or tumor infiltrating stromal cells is a key mediator of tumor growth and immune suppression at the tumor site. Nonetheless, clinical trials in cancer patients targeting the TGFβ pathway exhibited at best a modest ...
Yvonne Puplampu-Dove +5 more
doaj +1 more source